Medicaid reentry waivers now let 19 states cover treatment before release, opening a new, federally funded market for SUD providers built around the highest-risk moment in recovery.
Key Takeaways
- Reentry is a mortality crisis: People leaving incarceration face a sharply elevated risk of fatal overdose in the first weeks out, when coverage and treatment have historically lapsed. Continuity of care at release is a life-or-death gap.
- The inmate exclusion is finally bending: A federal waiver now lets states use Medicaid to cover certain services in the 90 days before release, an exception to a decades-old ban. Nineteen states have approval and more are pending.
- A suspend-not-terminate rule now backs it up: As of January 2026, states must suspend rather than cancel Medicaid during incarceration, smoothing the handoff to community care. It is a quiet but consequential structural fix.
- It is a real market for SUD providers: Reentry mandates medication-assisted treatment, case management, and a supply of medication at release, work community providers are positioned to deliver. The opportunity is genuine, and so is the execution risk.
The most dangerous moment in an addicted person’s life is often not the one you would guess. It is not the height of their using, or the overdose that lands them in an emergency room, or the arrest that follows. It is the morning they walk out of a jail or prison, clean after weeks or months of enforced abstinence, tolerance gone, and step back into the same neighborhood and the same supply that nearly killed them the first time.
The research on this is grim, albeit consistent. In the first weeks after release, the risk of a fatal overdose spikes far above the baseline, because a body that has lost its tolerance meets a drug supply that has only grown more lethal. For years, the American health-care system managed this lethal handoff about as badly as it could, by making sure that the person walking through the gate had no insurance, no medication, and no appointment waiting for them.
That is beginning to change, through a policy shift that is technical enough to have drawn little public attention and consequential enough to open a genuinely new market in addiction care. Medicaid, long forbidden by law from paying for almost any care delivered to people who are incarcerated, is now being allowed to reach through the walls in the weeks before release, and to do it specifically for the substance-use and mental-health conditions that make reentry so deadly.
How Medicaid Reentry Waivers Bend the Inmate Exclusion
The barrier being dismantled is old and blunt. Since Medicaid’s creation, an inmate exclusion has barred the program from paying for the care of people held in jails and prisons, with a narrow exception for inpatient hospital stays, which left correctional health care as a separate, state-and-county-funded world with almost no bridge to the community programs a person would need after release. In April 2023, federal regulators opened a route around that wall, inviting states to apply for a section 1115 demonstration waiver that would let Medicaid cover a defined package of services in the period up to ninety days before a person’s expected release, a partial and carefully bounded waiver of the exclusion built on a mandate Congress had written into the bipartisan SUPPORT Act.
The uptake has been steady. Nineteen states now hold approved reentry waivers, with several more plus the District of Columbia pending, and California, the first to implement, has been running its version since late 2024. The federal government set a floor for what these waivers must cover, and it is pointed squarely at addiction: at a minimum, states have to provide case management, medication-assisted treatment for substance use disorders together with counseling, and a thirty-day supply of prescription medication handed to the person as they walk out. The design reflects a simple recognition, that continuity through the gate is the thing that keeps people alive, and that the medication and the case manager have to be arranged before release, not after.
A Rare Medicaid Expansion That Survived the Turnover
What makes reentry unusual in the current Medicaid landscape is that it has proved durable across a political transition that has been hard on other coverage expansions. Many initiatives approved in recent years now face a colder reception, and some are being allowed to expire. Reentry has largely held, and the reason is instructive: its legal foundation was laid by the SUPPORT Act, an opioid-response law passed with broad bipartisan support and signed during the first Trump administration, which makes reentry care harder to caricature as a partisan project. Reducing overdose deaths, cutting the odds that a person cycles back into custody, and easing costs on jails and prisons are goals that draw support across the aisle, and Republican and Democratic governors alike have pursued these waivers.
A second, quieter structural change reinforces the first. Under a provision that took effect at the start of 2026, states must now suspend rather than terminate a person’s Medicaid coverage when they are incarcerated, so that eligibility can be switched back on at release instead of rebuilt from scratch through a weeks-long reapplication that, in practice, often meant a person went uncovered during exactly the window when they were most likely to die. Paired with the reentry waivers, the suspend-not-terminate rule turns the release date from a coverage cliff into something closer to a warm handoff, at least on paper. Whether it works that way in practice depends on the harder part, which is execution.
The Reentry Opportunity for SUD Providers
For community substance-use providers, reentry represents something the field rarely sees: a new, federally funded stream of demand aimed at a population with intense clinical need and, historically, almost no access. Someone must deliver the pre-release medication-assisted treatment, staff the case management that links a person to care on the outside, and stand ready to receive that person into a community program on the day of release, and correctional systems, whose expertise is custody rather than addiction medicine, are not built to do it alone. That gap is the opening. Providers who can operate at the awkward seam between the carceral and community systems, credential clinicians to work inside facilities, and manage the logistics of a warm handoff are positioned to serve a market that federal law kept closed until three years ago.
It fits a broader pattern Acuity has tracked, in which addiction care keeps being pulled toward integration and coordination even as the financing lurches, the same impulse visible in the growth of collaborative and integrated care models and in the persistent struggle to pay for care that crosses traditional silos between mental health and substance-use treatment. Reentry sits at one of the most extreme of those seams, the one between corrections and community, and the providers who learn to work it will be building relationships with state Medicaid agencies and correctional systems that are difficult to establish and, once established, difficult for a competitor to dislodge.
Why Reentry Is Not Easy Money
None of this is easy money, and treating it that way is the fastest route to failing at it. Reentry programs run headlong into the practical friction of two systems that were never designed to talk to each other: correctional facilities with their own security priorities and information systems, Medicaid agencies with their own eligibility and billing rules, and, in the middle, a patient who may be released early, transferred, or lost to the process before the carefully arranged handoff can happen. Data sharing across that boundary is notoriously hard, and the waivers themselves are time-limited demonstrations whose renewal, like every 1115 waiver, depends on federal priorities that can shift. The broader Medicaid environment adds its own turbulence, with the coverage contractions and administrative churn that Acuity has documented as the H.R. 1 restructuring reshapes the program in nearly every state threatening to complicate the eligibility handoffs that reentry depends on, and with new work-requirement rules that lean on the same substance-use exemptions and records-privacy limits that govern this population.
The realistic posture, then, is the same one that fits most real openings in this field: engage early, build the operational muscle before the demand fully arrives, and do not mistake a policy opening for a finished market. Reentry is a rare instance of Medicaid policy moving to meet a mortality crisis at exactly the point where intervention saves the most lives, and it has held together through a political climate that has not been kind to coverage. For providers willing to do the unglamorous work of bridging two systems that resist each other, it is one of the more meaningful openings in addiction care right now.
